Relevance of new drug discovery to reduce NF-κB activation in cardiovascular disease

Vascular Pharmacology

Volumn 57, Issue 1, 2012, Pages 41-47

  Madonna, Rosalinda ^a,b   De Caterina, Raffaele ^a,c  

^a UNIVERSITY OF CHIETI   (Italy)

^b TEXAS HEART INSTITUTE   (United States)

^c FONDAZIONE TOSCANA GABRIELE MONASTERIO   (Italy)

Author keywords

Atherosclerosis; Inflammation; NF B; Nuclear factor B

Indexed keywords

4 (2 AMINOETHYLAMINO) 1,8 DIMETHYLIMIDAZO[1,2 A]QUINOXALINE; [1 METHYL 1,5 DIHYDRO 2 AMINO 5 [4 (MESYL)BENZYLIDENE] 4H IMIDAZOLE 4 ONE MESILATE]; ACETYLCYSTEINE; ACETYLSALICYLIC ACID; B CELL ACTIVATING FACTOR; BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; BETAINE; BORTEZOMIB; CHEMOKINE RECEPTOR CXCR4; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; DOCOSAHEXAENOIC ACID; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; ICOSAPENTAENOIC ACID; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1BETA; INTERLEUKIN 6; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MG 115; MONOCYTE CHEMOTACTIC PROTEIN 1; PHOSPHOLIPASE A2; PROBUCOL; PROTEIN P52; RANTES; SALINOSPORAMIDE A; STROMAL CELL DERIVED FACTOR 1; SUCCINOBUCOL; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1;

ADAPTIVE IMMUNITY; ARTHRITIS; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; DRUG STRUCTURE; ENCEPHALOMYELITIS; HEART INFARCTION; HUMAN; INNATE IMMUNITY; KIDNEY DISEASE; LIVER DISEASE; NONHUMAN; PRIORITY JOURNAL; RETINITIS; REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION; STROKE; UNSTABLE ANGINA PECTORIS;

ANIMALS; CARDIOVASCULAR DISEASES; DRUG DISCOVERY; HUMANS; INFLAMMATION; NF-KAPPA B; SIGNAL TRANSDUCTION;

EID: 84862528749     PISSN: 15371891     EISSN: 18793649     Source Type: Journal    
DOI: 10.1016/j.vph.2012.02.005     Document Type: Review

References (72)

1. Ahn K.S., Sethi G., Chao T.H., Neuteboom S.T., Chaturvedi M.M., Palladino M.A., Younes A., Aggarwal B.B. Salinosporamide A (NPI-0052) potentiates apoptosis, suppresses osteoclastogenesis, and inhibits invasion through down-modulation of NF-kappaB regulated gene products. Blood 2007, 110:2286-2295.
2. Blackwell T.S., Blackwell T.R., Holden E.P., Christman B.W., Christman J.W. In vivo antioxidant treatment suppresses nuclear factor-kappa B activation and neutrophilic lung inflammation. J. Immunol. 1996, 157:1630-1637.
3. Bogyo M., Wang E.W. Proteasome inhibitors: complex tools for a complex enzyme. Curr. Top. Microbiol. Immunol. 2002, 268:185-208.
4. Bonizzi G., Karin M. The two NF-kappaB activation pathways and their role in innate and adaptive immunity. Trends Immunol. 2004, 25:280-288.
5. Brand K., Page S., Rogler G., Bartsch A., Brandl R., Knuechel R., Page M., Kaltschmidt C., Baeuerle P.A., Neumeier D. Activated transcription factor nuclear factor-kappa B is present in the atherosclerotic lesion. J. Clin. Invest. 1996, 97:1715-1722.
6. Burke J.R., Pattoli M.A., Gregor K.R., Brassil P.J., MacMaster J.F., McIntyre K.W., Yang X., Iotzova V.S., Clarke W., Strnad J., Qiu Y., Zusi F.C. BMS-345541 is a highly selective inhibitor of I kappa B kinase that binds at an allosteric site of the enzyme and blocks NF-kappa B-dependent transcription in mice. J. Biol. Chem. 2003, 278:1450-1456.
7. Chen H., Charlat O., Tartaglia L.A., Woolf E.A., Weng X., Ellis S.J., Lakey N.D., Culpepper J., Moore K.J., Breitbart R.E., Duyk G.M., Tepper R.I., Morgenstern J.P. Evidence that the diabetes gene encodes the leptin receptor: identification of a mutation in the leptin receptor gene in db/db mice. Cell 1996, 84:491-495.
8. Chen L., Zhao Q., Wang X.L., You R., Zhang Y.H., Ji H., Lai Y.S. ZLJ-6, a novel COX/5-LOX inhibitor, attenuates TNF-alpha-induced endothelial E-selectin, ICAM-1 and VCAM-1 expression and monocyte-endothelial interactions via a COX/5-LOX-independent mechanism. Vascul. Pharmacol. 2011, 55(5-6):135-142.
9. Costanzo A., Moretti F., Burgio V.L., Bravi C., Guido F., Levrero M., Puri P.L. Endothelial activation by angiotensin II through NFkappaB and p38 pathways: Involvement of NFkappaB-inducible kinase (NIK), free oxygen radicals, and selective inhibition by aspirin. J. Cell. Physiol. 2003, 195:402-410.
10. Cuzzocrea S., Chatterjee P.K., Mazzon E., Dugo L., Serraino I., Britti D., Mazzullo G., Caputi A.P., Thiemermann C. Pyrrolidine dithiocarbamate attenuates the development of acute and chronic inflammation. Br. J. Pharmacol. 2002, 135:496-510.
11. Cvek B., Dvorak Z. Targeting of nuclear factor-kappaB and proteasome by dithiocarbamate complexes with metals. Curr. Pharm. Des. 2007, 13:3155-3167.
12. Cybulsky M.I., Gimbrone M.A. Endothelial expression of a mononuclear leukocyte adhesion molecule during atherogenesis. Science 1991, 251:788-791.
13. D'Acquisto F., Iuvone T., Rombola L., Sautebin L., Di Rosa M., Carnuccio R. Involvement of NF-kappaB in the regulation of cyclooxygenase-2 protein expression in LPS-stimulated J774 macrophages. FEBS Lett. 1997, 418:175-178.
14. Dannhardt G., Laufer S. Structural approaches to explain the selectivity of COX-2 inhibitors: is there a common pharmacophore?. Curr. Med. Chem. 2000, 7:1101-1112.
15. De Caterina R. Endothelial dysfunctions: common denominators in vascular disease. Curr. Opin. Clin. Nutr. Metab. Care 2000, 3:453-467.
16. De Caterina R. n-3 fatty acids in cardiovascular disease. N. Engl. J. Med. 2011, 364:2439-2450.
17. De Caterina R., Madonna R., Massaro M. Effects of omega-3 fatty acids on cytokines and adhesion molecules. Curr. Atheroscler Rep. 2004, 6:485-491.
18. Fujihara C.K., Antunes G.R., Mattar A.L., Malheiros D.M., Vieira J.M., Zatz R. Chronic inhibition of nuclear factor-kappaB attenuates renal injury in the 5/6 renal ablation model. Am. J. Physiol. Renal. Physiol. 2007, 292:F92-F99.
19. Gareus R., Kotsaki E., Xanthoulea S., van der Made I., Gijbels M.J., Kardakaris R., Polykratis A., Kollias G., de Winther M.P., Pasparakis M. Endothelial cell-specific NF-kappaB inhibition protects mice from atherosclerosis. Cell Metab. 2008, 8:372-383.
20. Gaziano J.M., Manson J.E., Branch L.G., Colditz G.A., Willett W.C., Buring J.E. A prospective study of consumption of carotenoids in fruits and vegetables and decreased cardiovascular mortality in the elderly. Ann. Epidemiol. 1995, 5:255-260.
21. Go E.K., Jung K.J., Kim J.Y., Yu B.P., Chung H.Y. Betaine suppresses proinflammatory signaling during aging: the involvement of nuclear factor-kappaB via nuclear factor-inducing kinase/IkappaB kinase and mitogen-activated protein kinases. J. Gerontol. A Biol. Sci. Med. Sci. 2005, 60:1252-1264.
22. Groll M., Huber R., Potts B.C. Crystal structures of Salinosporamide A (NPI-0052) and B (NPI-0047) in complex with the 20S proteasome reveal important consequences of beta-lactone ring opening and a mechanism for irreversible binding. J. Am. Chem. Soc. 2006, 128:5136-5141.
23. Gu X.P., Qiu Y.D., Xu F.T., Jiang Y., Ding Y.T. In vivo suppressive effect of nuclear factor-kappaB inhibitor on neutrophilic inflammation of grafts after orthotopic liver transplantation in rats. World J. Gastroenterol. 2004, 10:3654-3658.
24. Gupta S.C., Sundaram C., Reuter S., Aggarwal B.B. Inhibiting NF-kappaB activation by small molecules as a therapeutic strategy. Biochim. Biophys. Acta 2010, 1799:775-787.
25. Hayden M.S., Ghosh S. Signaling to NF-kappaB. Genes Dev. 2004, 18:2195-2224.
26. He F.J., Nowson C.A., MacGregor G.A. Fruit and vegetable consumption and stroke: meta-analysis of cohort studies. Lancet 2006, 367:320-326.
27. Kazmi S.M., Plante R.K., Visconti V., Taylor G.R., Zhou L., Lau C.Y. Suppression of NF kappa B activation and NF kappa B-dependent gene expression by tepoxalin, a dual inhibitor of cyclooxygenase and 5-lipoxygenase. J. Cell. Biochem. 1995, 57:299-310.
28. Kitamei H., Iwabuchi K., Namba K., Yoshida K., Yanagawa Y., Kitaichi N., Kitamura M., Ohno S., Onoe K. Amelioration of experimental autoimmune uveoretinitis (EAU) with an inhibitor of nuclear factor-kappaB (NF-kappaB), pyrrolidine dithiocarbamate. J. Leukoc. Biol. 2006, 79:1193-1201.
29. Kopp E., Ghosh S. Inhibition of NF-kappa B by sodium salicylate and aspirin. Science 1994, 265:956-959.
30. Kris-Etherton P.M., Lichtenstein A.H., Howard B.V., Steinberg D., Witztum J.L. Antioxidant vitamin supplements and cardiovascular disease. Circulation 2004, 110:637-641.
31. Langer T., Hoffmann R.D. Pharmacophores and Pharmacophore Searches 2006, WILEY-VCH. I. Weinheim (Ed.).
32. Laufer S. Discovery and development of ML3000. Inflammopharmacology 2001, 9:101-112.
33. Li T., Morgan M.J., Choksi S., Zhang Y., Kim Y.S., Liu Z.G. MicroRNAs modulate the noncanonical transcription factor NF-kappaB pathway by regulating expression of the kinase IKKalpha during macrophage differentiation. Nat. Immunol. 2010, 11:799-805.
34. Liu S., Lee I.M., Ajani U., Cole S.R., Buring J.E., Manson J.E. Intake of vegetables rich in carotenoids and risk of coronary heart disease in men: the physicians' health study. Int. J. Epidemiol. 2001, 30:130-135.
35. Madge L.A., May M.J. Classical NF-kappaB activation negatively regulates noncanonical NF-kappaB-dependent CXCL12 expression. J. Biol. Chem. 2010, 285:38069-38077.
36. Madonna R., De Caterina R. Prolonged exposure to high insulin impairs the endothelial PI3-kinase/Akt/nitric oxide signalling. Thromb. Haemost. 2009, 101:345-350.
37. Madonna R., Pandolfi A., Massaro M., Consoli A., De Caterina R. Insulin enhances vascular cell adhesion molecule-1 expression in human cultured endothelial cells through a pro-atherogenic pathway mediated by p38 mitogen-activated protein-kinase. Diabetologia 2004, 47:532-536.
38. Madonna R., Massaro M., Pandolfi A., Consoli A., De Caterina R. The prominent role of p38 mitogen-activated protein kinase in insulin-mediated enhancement of VCAM-1 expression in endothelial cells. Int. J. Immunopathol. Pharmacol. 2007, 20:539-555.
39. Madonna R., Massaro M., De Caterina R. Insulin potentiates cytokine-induced VCAM-1 expression in human endothelial cells. Biochim. Biophys. Acta 2008, 1782:511-516.
40. Madonna R., De Caterina R., Willerson J.T., Geng Y. Co-activation of nuclear factor-kappaB and myocardin/serum response factor in canine cardiac myoblasts exposed to high levels of insulin. J. Am. Coll. Cardiol. 2011, 57:207. 10.1016/S0735-1097(11)60207-6.
41. Madonna R., Salerni S., Schiavone D., Glatz J.F., Geng Y.J., De Caterina R. Omega-3 fatty acids attenuate constitutive and insulin-induced CD36 expression through a suppression of PPAR alpha/gamma activity in microvascular endothelial cells. Thromb. Haemost. 2011, 106:500-510.
42. Massaro M., Habib A., Lubrano L., Del Turco S., Lazzerini G., Bourcier T., Weksler B.B., De Caterina R. The omega-3 fatty acid docosahexaenoate attenuates endothelial cyclooxygenase-2 induction through both NADP(H) oxidase and PKC epsilon inhibition. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:15184-15189.
43. Meng C.Q., Somers P.K., Rachita C.L., Holt L.A., Hoong L.K., Zheng X.S., Simpson J.E., Hill R.R., Olliff L.K., Kunsch C., Sundell C.L., Parthasarathy S., Saxena U., Sikorski J.A., Wasserman M.A. Novel phenolic antioxidants as multifunctional inhibitors of inducible VCAM-1 expression for use in atherosclerosis. Bioorg. Med. Chem. Lett. 2002, 12:2545-2548.
44. Monaco C., Paleolog E. Nuclear factor kappaB: a potential therapeutic target in atherosclerosis and thrombosis. Cardiovasc. Res. 2004, 61:671-682.
45. Morris C.D., Carson S. Routine vitamin supplementation to prevent cardiovascular disease: a summary of the evidence for the U.S. Preventive Services Task Force. Ann. Intern. Med. 2003, 139:56-70.
46. Mosca L., Benjamin E.J., Berra K., Bezanson J.L., Dolor R.J., Lloyd-Jones D.M., Newby L.K., Pina I.L., Roger V.L., Shaw L.J., Zhao D., Beckie T.M., Bushnell C., D'Armiento J., Kris-Etherton P.M., Fang J., Ganiats T.G., Gomes A.S., Gracia C.R., Haan C.K., Jackson E.A., Judelson D.R., Kelepouris E., Lavie C.J., Moore A., Nussmeier N.A., Ofili E., Oparil S., Ouyang P., Pinn V.W., Sherif K., Smith S.C., Sopko G., Chandra-Strobos N., Urbina E.M., Vaccarino V., Wenger N.K. Effectiveness-based guidelines for the prevention of cardiovascular disease in women-2011 update: a guideline from the american heart association. Circulation 2011, 123:1243-1262.
47. Newby A.C. Metalloproteinase expression in monocytes and macrophages and its relationship to atherosclerotic plaque instability. Arterioscler. Thromb. Vasc. Biol. 2008, 28:2108-2114.
48. Osganian S.K., Stampfer M.J., Rimm E., Spiegelman D., Hu F.B., Manson J.E., Willett W.C. Vitamin C and risk of coronary heart disease in women. J. Am. Coll. Cardiol. 2003, 42:246-252.
49. Osganian S.K., Stampfer M.J., Rimm E., Spiegelman D., Manson J.E., Willett W.C. Dietary carotenoids and risk of coronary artery disease in women. Am. J. Clin. Nutr. 2003, 77:1390-1399.
50. Pahan K., Schmid M. Activation of nuclear factor-kB in the spinal cord of experimental allergic encephalomyelitis. Neurosci. Lett. 2000, 287:17-20.
51. Rimm E.B., Stampfer M.J., Ascherio A., Giovannucci E., Colditz G.A., Willett W.C. Vitamin E consumption and the risk of coronary heart disease in men. N. Engl. J. Med. 1993, 328:1450-1456.
52. Roth G.J., Stanford N., Majerus P.W. Acetylation of prostaglandin synthase by aspirin. Proc. Natl. Acad. Sci. U. S. A. 1975, 72:3073-3076.
53. Ryu Y.S., Lee J.H., Seok J.H., Hong J.H., Lee Y.S., Lim J.H., Kim Y.M., Hur G.M. Acetaminophen inhibits iNOS gene expression in RAW 264.7 macrophages: differential regulation of NF-kappaB by acetaminophen and salicylates. Biochem. Biophys. Res. Commun. 2000, 272:758-764.
54. Saremi A., Arora R. Vitamin E and cardiovascular disease. Am. J. Ther. 2010, 17:e56-e65.
55. Scheuren N., Bang H., Munster T., Brune K., Pahl A. Modulation of transcription factor NF-kappaB by enantiomers of the nonsteroidal drug ibuprofen. Br. J. Pharmacol. 1998, 123:645-652.
56. Schoonbroodt S., Piette J. Oxidative stress interference with the nuclear factor-kappa B activation pathways. Biochem. Pharmacol. 2000, 60:1075-1083.
57. Schreck R., Rieber P., Baeuerle P.A. Reactive oxygen intermediates as apparently widely used messengers in the activation of the NF-kappa B transcription factor and HIV-1. EMBO J. 1991, 10:2247-2258.
58. Senftleben U., Cao Y., Xiao G., Greten F.R., Krahn G., Bonizzi G., Chen Y., Hu Y., Fong A., Sun S.C., Karin M. Activation by IKKalpha of a second, evolutionary conserved, NF-kappa B signaling pathway. Science 2001, 293:1495-1499.
59. Smale S.T. Hierarchies of NF-kappaB target-gene regulation. Nat. Immunol. 2011, 12:689-694.
60. Staudt L.M. Gene expression profiling of lymphoid malignancies. Annu. Rev. Med. 2002, 53:303-318.
61. Sun S.C. Non-canonical NF-kappaB signaling pathway. Cell Res. 2010, 21:71-85.
62. Sundell C.L., Somers P.K., Meng C.Q., Hoong L.K., Suen K.L., Hill R.R., Landers L.K., Chapman A., Butteiger D., Jones M., Edwards D., Daugherty A., Wasserman M.A., Alexander R.W., Medford R.M., Saxena U. AGI-1067: a multifunctional phenolic antioxidant, lipid modulator, anti-inflammatory and antiatherosclerotic agent. J. Pharmacol. Exp. Ther. 2003, 305:1116-1123.
63. Takimoto C.H., Calvo E. Principles of Oncologic Pharmacotherapy. Cancer Management: A Multidisciplinary Approach 2008, R. Pazdur, L.D. Wagman, K.A. Camphausen, W.J. Hoskins (Eds.).
64. Tamada S., Nakatani T., Asai T., Tashiro K., Komiya T., Sumi T., Okamura M., Kim S., Iwao H., Kishimoto T., Yamanaka S., Miura K. Inhibition of nuclear factor-kappaB activation by pyrrolidine dithiocarbamate prevents chronic FK506 nephropathy. Kidney Int. 2003, 63:306-314.
65. Tardif J.C., McMurray J.J., Klug E., Small R., Schumi J., Choi J., Cooper J., Scott R., Lewis E.F., L'Allier P.L., Pfeffer M.A. Effects of succinobucol (AGI-1067) after an acute coronary syndrome: a randomised, double-blind, placebo-controlled trial. Lancet 2008, 371:1761-1768.
66. Tosco P., Lazzarato L. Mechanistic insights into cyclooxygenase irreversible inactivation by aspirin. Chem. Med. Chem. 2009, 4:939-945.
67. Tsukamoto S., Yokosawa H. Targeting the proteasome pathway. Expert Opin. Ther. Targets 2009, 13:605-621.
68. Weber C., Erl W., Pietsch A., Weber P.C. Aspirin inhibits nuclear factor-kappa B mobilization and monocyte adhesion in stimulated human endothelial cells. Circulation 1995, 91:1914-1917.
69. Yamamoto Y., Yin M.J., Lin K.M., Gaynor R.B. Sulindac inhibits activation of the NF-kappaB pathway. J. Biol. Chem. 1999, 274:27307-27314.
70. Yin M.J., Yamamoto Y., Gaynor R.B. The anti-inflammatory agents aspirin and salicylate inhibit the activity of I(kappa)B kinase-beta. Nature 1998, 396:77-80.
71. Yoo C.G., Lee S., Lee C.T., Kim Y.W., Han S.K., Shim Y.S. Effect of acetylsalicylic acid on endogenous I kappa B kinase activity in lung epithelial cells. Am. J. Physiol. Lung Cell Mol. Physiol. 2001, 280:L3-L9.
72. Zhang W., Xing S.S., Sun X.L., Xing Q.C. Overexpression of activated nuclear factor-kappa B in aorta of patients with coronary atherosclerosis. Clin. Cardiol. 2009, 32:E42-E47.